Is Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Arcutis Biotherapeutics, Inc. at current levels.
ZORYVE is becoming dermatology's default non-steroidal, and the market still prices Arcutis like a one-drug story flirting with breakeven.
Where ARQT is headed
Walk into a US dermatology clinic in 2027 and the prescribing pattern looks different from what it did three years ago. Topical steroids still get written, but for the chronic inflammatory stuff (plaque psoriasis, atopic dermatitis, seborrheic dermatitis, scalp psoriasis), the reflex script for a growing share of derms is roflumilast. That is ZORYVE, and Arcutis owns it across cream, foam, and the indications it keeps stacking. Revenue grew 60% over the trailing year off a base that is still small relative to the addressable patient pool, which numbers in the tens of millions in the US alone across the labelled indications.
Read the full Compass Direction on ARQT
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $25.58).
See the full ARQT analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Arcutis Biotherapeutics, Inc. at current levels. ZORYVE is becoming dermatology's default non-steroidal, and the market still prices Arcutis like a one-drug story flirting with breakeven.
What is ARQT's Compass Score?
Arcutis Biotherapeutics, Inc. scores 78/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for ARQT?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the ARQT page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.